Featured Press Releases

Anixa Biosciences has unveiled its Phase 2 study plan for a breast cancer vaccine.

Anixa Biosciences has unveiled its Phase 2 study plan for a breast cancer vaccine.

CollPlant Biotechnologies Announces First Quarter 2025 Financial Results and Issues Corporate Update

CollPlant Biotechnologies Announces First Quarter 2025 Financial Results and Issues Corporate Update

  • 28 May 2025

CollPlant Biotechnologies a regenerative and aesthetics medicine company developing innovative...

Gedeon Richter Chooses Trial Interactive for Streamlined Clinical Trial Management

Gedeon Richter Chooses Trial Interactive for Streamlined Clinical Trial Management

Scientific article highlights Namodenoson as promising for advanced liver cancer and MASH

Scientific article highlights Namodenoson as promising for advanced liver cancer and MASH

Isotopia collaborates with LIVEKIDNEY.BIO, marking a breakthrough in lupus treatment advancements

Isotopia collaborates with LIVEKIDNEY.BIO, marking a breakthrough in lupus treatment advancements

IKA introduces new accessories for the HABITAT research bioreactor.

IKA introduces new accessories for the HABITAT research bioreactor.

Johnson & Johnson Announces U.S. Food and Drug Administration Approval of TECVAYLI + DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma.

Johnson & Johnson Announces U.S. Food and Drug Administration Approval of TECVAYLI + DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma.

  • Johnson & Johnson
  • 06 Mar 2026
ulrich medical USA® Expands Commitment to Evidence-Based Spine Innovation; Appoints Alissa Calaway, RN, MSN as Director of U.S. Clinical Affairs

ulrich medical USA® Expands Commitment to Evidence-Based Spine Innovation; Appoints Alissa Calaway, RN, MSN as Director of U.S. Clinical Affairs

  • ulrich medical USA
  • 06 Mar 2026
Cognito Therapeutics Announces $105 Million Oversubscribed Series C Financing to Advance Spectris™ in Alzheimer’s Disease.

Cognito Therapeutics Announces $105 Million Oversubscribed Series C Financing to Advance Spectris™ in Alzheimer’s Disease.

  • Cognito Therapeutics
  • 05 Mar 2026
Eton Pharmaceuticals Strengthens Rare Disease Portfolio with U.S. Commercialization Rights to HEMANGEOL® Oral Solution

Eton Pharmaceuticals Strengthens Rare Disease Portfolio with U.S. Commercialization Rights to HEMANGEOL® Oral Solution

  • Eton Pharmaceuticals
  • 04 Mar 2026
FTC Warns PBM Practices Drive Higher Drug Costs as Employers Push Back

FTC Warns PBM Practices Drive Higher Drug Costs as Employers Push Back

  • US-Rx
  • 03 Mar 2026
30% Lower Risk With WELIREG® + LENVIMA® vs. Cabozantinib in Previously Treated RCC

30% Lower Risk With WELIREG® + LENVIMA® vs. Cabozantinib in Previously Treated RCC

  • Merck & Co., Inc.
  • 03 Mar 2026
World Drug Delivery Summit 2025
The Digital Pharma Advances Conference 2026

Most Popular
March   2026
M T W T F S S
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31          

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.